Statera BioPharma (Statera BioPharma) Total Current Assets : $1.22 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Statera BioPharma's total current assets for the quarter that ended in Sep. 2022 was $1.22 Mil.

Statera BioPharma Total Current Assets Historical Data

The historical data trend for Statera BioPharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Total Current Assets Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Total Current Assets

0.93

4.16

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Current Assets	Get a 7-Day Free Trial						13.34	4.16	1.45	1.68	1.22

Statera BioPharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Statera BioPharma's Total Current Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1.979	+	0.349	+	0	+	1.827
	=	4.16

Statera BioPharma's Total Current Assets for the quarter that ended in Sep. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.506	+	0.361	+	0	+	0.355
	=	1.22

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Statera BioPharma (OTCPK:STAB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Statera BioPharma's Liquidation Value for the quarter that ended in Sep. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.506	-	22.917	+	0.75 * 0.183	+	0.5 * 0
=	-22.27

Statera BioPharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (Statera BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Executives

Satishchandran Chandrasekhar	director	167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka	director, officer: Chief Operating Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit	officer: Chief Technology Officer	C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M.	officer: Chief Legal Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky	officer: Chief Medical Officer	2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam	officer: Chief Financial Officer	2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick	director	TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh	officer: Vice President of Finance	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin	director	73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo	officer: Principal Financial Officer	73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin	director	73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy	director	73 HIGH STREET, BUFFALO NY 14203
Lea Verny	director	73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev	director	73 HIGH STREET, BUFFALO NY 14203